Overview

Pemigatinib tablets are supplied in three strengths, 4.5 mg, 9 mg, and 13.5 mg, which exist to support dose selection and adjustment in FGFR2-rearranged cholangiocarcinoma. For distributors and hospital pharmacies, sourcing the medicine means planning around that strength range, the cycle-based regimen, and controlled storage rather than treating it like a single-SKU product.

Strength Range and Cycle Dosing

The 13.5 mg strength anchors the standard schedule of 14 days on therapy followed by 7 days off in repeating 21-day cycles. The lower strengths matter when dose reduction is needed for tolerability. Buyers should stock the full range so that adjustments can be made without interrupting treatment continuity for an individual patient.

Storage and Handling

The tablets are stored at controlled room temperature, with limited permitted excursions, and should be kept in their original packaging away from moisture. Because oncology products carry chain-of-custody expectations, temperature logging during transit and on receipt is a reasonable sourcing control even when active cold chain is not mandated.

Qualifying the Supply

Robust supply begins with supplier qualification. Request current good manufacturing practice documentation, certificates of analysis, and batch traceability for each shipment. Confirm lead times and minimum order quantities that match your demand cycle, and agree on a recall and return process. These steps protect patients and reduce the operational risk of stockouts.

Demand Planning Across Markets

Stocking three strengths complicates forecasting but improves patient continuity when dose changes are needed. Buyers should align orders with local treatment volume and the expected proportion of patients who will require reduction. Regional import rules may require specific licensing for oncology products, so early engagement with customs and regulatory contacts prevents delays. Building a buffer for the lower strengths is prudent, since interruptions in those sizes are harder to substitute than the main 13.5 mg presentation. Documentation discipline also matters: retaining batch records and expiry tracking protects against waste and supports recall readiness. A simple inventory rule that rotates stock by expiry date keeps the supply both compliant and usable across the treatment cycle.

FAQ

Q: Why are there three different tablet strengths? A: The strengths allow clinicians to initiate and later reduce the dose according to tolerability while keeping the cycle schedule intact.

Q: Does pemigatinib require refrigerated transport? A: It is stored at controlled room temperature rather than refrigerated, though documented temperature control during shipping remains good practice.

Q: What documents should a B2B buyer request? A: GMP certificates, certificates of analysis, and batch-level traceability are the core documents for qualifying an oncology supplier.